GlassScriptPhysician profile
Karla A Gerald
NPI 1518299213
$6,532.41
in general payments reported to CMS, 2019-2025
41 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $1,286 · 2023: $1,681 · 2024: $1,327 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,500.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $882.22 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $865.74 | 2021-2025 | |
| Amgen INC. | $514.20 | 2021-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $427.82 | 2021-2025 | |
| Lilly USA, LLC | $424.97 | 2021-2025 | Mounjaro, Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $406.12 | 2022-2025 | Leqvio |
| Pfizer INC. | $353.87 | 2021-2025 | |
| Novo Nordisk INC | $311.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $294.77 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corcept Therapeutics | $212.90 | 2025 | Korlym |
| Lundbeck LLC | $204.64 | 2021-2024 | Vyepti |
| Acadia Pharmaceuticals INC | $170.17 | 2021-2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $134.36 | 2021-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Dexcom, INC. | $115.12 | 2021-2023 | Dexcom G6 Transmitter |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $100.91 | 2022-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $93.03 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $91.66 | 2021-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.32 | 2022-2025 | Jardiance |
| Averitas Pharma INC. | $69.02 | 2025 | Qutenza |
| Shield Therapeutics INC | $59.64 | 2023-2024 | Accrufer |
| Esperion Therapeutics, INC. | $55.48 | 2021-2024 | Nexletol |
| Astellas Pharma US INC | $45.14 | 2024-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $44.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.71 | 2021-2023 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $44.26 | 2021-2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $41.93 | 2022-2023 | Nuedexta |
| Merck Sharp & Dohme LLC | $37.45 | 2021-2025 | Capvaxive, Gardasil 9 |
| Impel Pharmaceuticals INC. | $36.30 | 2022-2023 | Trudhesa |
| Phathom Pharmaceuticals, INC. | $35.14 | 2024-2025 | Voquezna |
| Medtronic, INC. | $32.89 | 2024-2025 | Minimed 780g |
| Abbott Laboratories | $26.43 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $24.19 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Philips North America LLC | $20.24 | 2025 | Lm Undivided |
| Exact Sciences Corporation | $19.50 | 2025 | The Cologuard Plus Collection Kit |
| Ultragenyx Pharmaceutical INC. | $17.99 | 2024 | Crysvita |
| Sumitomo Pharma America, INC. | $17.41 | 2023 | Aptiom |
| Mdd US Operations, LLC | $17.06 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.29 | 2025 | Caplyta |
| Inari Medical, INC. | $15.15 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cequr Corporation | $10.00 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Gerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.